Zacks.com on MSN5d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
PMLive5d
Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study
The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...
PharmExec5d
Phase III Trial Data Show Uplizna Significantly Improves Symptoms of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
Nasdaq5d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.
MPR5d
Week 52 Data Show Inebilizumab Continues to Benefit in AChR+ Myasthenia Gravis
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Clinical Trials Arena on MSN3d
Immunovant will not seek approval for MG therapy, despite hitting endpoints
The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...